.Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03F_ProgestogensAndEstrogensInCombination.G03FA10_NorgestrelAndEstrogen.NorgestrelAndEstrogen .Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03F_ProgestogensAndEstrogensInCombination.G03FA10_NorgestrelAndEstrogen.NorgestrelAndEstrogen| name: | NorgestrelAndEstrogen |
| ATC code: | G03FA10 | route: | oral |
| n-compartments | 1 |
Norgestrel and estrogen is a combined oral contraceptive agent containing the progestin norgestrel and an estrogen, typically ethinylestradiol. This combination is used primarily for prevention of pregnancy. While highly effective as a contraceptive, some formulations are less commonly used in current clinical practice compared to newer generation products.
Estimated average pharmacokinetics for oral administration of norgestrel 0.3 mg and ethinylestradiol 0.03 mg in healthy adult women based on available literature for component drugs; no direct population PK model for the fixed combination was identified.
Kuhnz, W (1990). Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women. American journal of obstetrics and gynecology 163(6 Pt 2) 2120–2127. DOI:10.1016/0002-9378(90)90551-h PUBMED:https://pubmed.ncbi.nlm.nih.gov/2124087
Olsson, B, & Landgren, BM (2001). The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Clinical therapeutics 23(11) 1876–1888. DOI:10.1016/s0149-2918(00)89083-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11768839
Anderson, MS, et al., & Iwamoto, M (2011). Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. British journal of clinical pharmacology 71(4) 616–620. DOI:10.1111/j.1365-2125.2010.03885.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/21395656